Replies to post #139885 on Biotech Values

[oc631]

The investment question is will it be enough to justify the valuations we've seen?

There will be winners and losers. You can expect huge stockpiles of drugs from the first company to file a NDA and demand will be intense upon approval. Since ABT developed their combo in-house there's little downside risk and much to gain if GILD should stumble in GT1 treatment-naive patients.

And competition is literally breathing down GILD's neck

I disagree. GILD has a commanding lead with a safe, best-in-class drug in all genotypes. They have a pipeline full of mid-stage, plan B options.

Perhaps there's another dark horse developer out there? If GS-7977/Riba lacks potency in GT1 I feel ABT may be GILD's biggest threat in this genotype. I didn't read through the latest abstracts from the liver meeting. Who is breathing down GILD's neck with a credible oral combo? BMY?